ClinicalTrials.gg
CompletedNCT01938001AUGMENTUpdated Feb 22, 2023Results posted

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

A Phase 3 interventional study of Rituximab and Lenalidomide in Lymphoma, Non-Hodgkin, sponsored by Celgene. Completed at 160 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin — 2 open to participants now, 4 under way, 1 of them phase 3. Lenalidomide · Lymphoma, Non-Hodgkin.

Enrollment
3rd of 31
358 · median 46
Started
2013
with 2 others
Phase 3
4 of 32
none open now
Registered
20th of 32
by date
Lead sponsor
8 of 32
Celgene

Among the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2013, is one of 4 in phase 3, and was the 20th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.

Read the detailed description

Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is an immunomodulatory drug (a drug that affects the immune system) which alters the body's immune system and it may also interfere with the development of tiny blood vessels involved in tumor growth. Therefore, lenalidomide may reduce or prevent the growth of cancer cells. Lenalidomide has also been shown to restore the immune cells' ability to attack and kill tumor cells, an ability that may be inhibited by follicular lymphoma and other lymphomas. The combination of rituximab and lenalidomide may eliminate the cancer while restoring the immune system's ability to attack tumor cells.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Non-Hodgkins Follicular lymphoma, Non-Hodgkins Marginal zone lymphoma, treatment for follicular lymphoma, treatment for Marginal zone lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of signing the document.
  • Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  • confirmed marginal zone lymphoma or follicular lymphoma (grade 1, 2 or 3a; CD20+ by flow cytometry or histochemistry).
  • Previously treated with at least one prior systemic chemotherapy, immunotherapy or chemoimmunotherapy and have received at least 2 previous doses of rituximab.
  • Documented , refractory or progressive disease after treatment with systemic therapy and must not be rituximab-refractory.
  • Investigator considers rituximab monotherapy appropriate.
  • Bi-dimensionally on cross sectional imaging by X-ray computed tomography (CT) or magnetic resonance imaging (MRI).
  • Need of treatment for relapsed, progressed or refractory disease as assessed by the investigator.
  • (ECOG) performance status ≤ 2.
  • Adequate bone marrow function.
  • Willingness to follow study visit schedule, pregnancy precautions and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma.
  • Subjects taking during the last week prior to study treatment, unless administered at a dose equivalent to \< 20 mg/day prednisone or prednisolone.
  • Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 6 months.
  • Known seropositive for or active viral infection with virus (HBV) or/and (HIV).
  • Known virus (HCV) positive with chronic HCV or active viral infection with HCV hepatitis requiring anti-viral medication (at time of randomization).
  • \< 6 months.
  • Known sensitivity or allergy to murine products.
  • Prior history of , other than follicular or marginal zone lymphoma, unless the subject has been free of the disease for ≥ 5 years.
  • Prior use of lenalidomide.
  • Known allergy to thalidomide.
  • Neuropathy > Grade 1.
  • Presence or history of central nervous system involvement by lymphoma.
  • Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it.
  • Uncontrolled intercurrent illness.
  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the document.
  • Pregnant or lactating females.
  • Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    Rituximab and Lenalidomide

    Participants received rituximab 375 mg/m\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.

    Drug: Rituximab · Drug: Lenalidomide

  • Active comparator
    Rituximab and Placebo

    Participants received riituximab 375 mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.

    Drug: Rituximab · Drug: Placebo

Interventions

  • Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5

    Also known as: Rituxan

  • Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles

    Also known as: CC-5013, Revlimid

  • DrugPlacebo

    Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days

06

What researchers measure

Primary outcomes

  1. Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)

    Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules.

    Time frame: From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).

Secondary outcomes

  1. Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC

    DCCR was defined as the percentage of participants with a best response of complete response (CR) that lasted no less than one year (≥ 48 weeks) during the study prior to administration of new anti-lymphoma therapy. A CR is defined as a complete disappearance of any disease-related symptoms and normalization of biochemical abnormalities.

    Time frame: From first dose of investigational product (IP) to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomiade arm and 11.04 months in the rituximab/placebo arm

  2. Kaplan-Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

    Time frame: From date of randomization to death due to any cause (Average of 55.71 months and a maximum up to 95.2 months)

  3. Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC

    Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.

    Time frame: From date of first dose to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm

  4. Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC

    Percentage of participants with a best response of at CR during the study without administration of new anti-lymphoma therapy. A CR = Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.

    Time frame: From date of first dose up to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm

  5. Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC

    Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.

    Time frame: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).

  6. Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC

    DOCR was defined as the time from initial CR until documented PD or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.

    Time frame: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).

  7. Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC

    Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date.

    Time frame: From date of randomization to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).

  8. Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)

    Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study.

    Time frame: From date of randomization to date of first documented administration of a new anti-lymphoma treatment (Average of 55.71 months and a maximum up to 95.2 months)

  9. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs include AEs that started or worsened between the date of the first dose and 28 days after the date of the last dose. A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death

    Time frame: From first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months)

07

Results

Posted Aug 13, 2019

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneRituximab + Lenalidomide (R^2)Rituximab + Placebo
Started178180
Completed176180
Not completed20
Withdrew: Adverse event unrelated to study drug10
Withdrew: Death10
Treatment
Participant flow — Treatment
MilestoneRituximab + Lenalidomide (R^2)Rituximab + Placebo
Started176180
Completed124110
Not completed5270
Withdrew: Death20
Withdrew: Adverse event148
Withdrew: Progressive disease2154
Withdrew: Withdrawal by subject137
Withdrew: Other reasons21

Outcome measures

PrimaryKaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)

Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules.

Time frame:
From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Reported as:
Median · months
Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)
monthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)39.4 (22.9 to NA)14.1 (11.4 to 16.7)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.46 · 95% CI 0.34 to 0.62Hazard ratio and its confidence interval (CI) were estimated from Cox proportional hazard model adjusting for the stratification factors noted above.
SecondaryDurable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC

DCCR was defined as the percentage of participants with a best response of complete response (CR) that lasted no less than one year (≥ 48 weeks) during the study prior to administration of new anti-lymphoma therapy. A CR is defined as a complete disappearance of any disease-related symptoms and normalization of biochemical abnormalities.

Time frame:
From first dose of investigational product (IP) to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomiade arm and 11.04 months in the rituximab/placebo arm
Reported as:
Number · Percentage of Participants
Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC
Percentage of ParticipantsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC25.3 (19.1 to 32.3)11.1 (6.9 to 16.6)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Cochran-Mantel-Haenszel · p = 0.0006Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \> 2 years), and disease histology (FL, MZL).
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Time frame:
From date of randomization to death due to any cause (Average of 55.71 months and a maximum up to 95.2 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Overall Survival (OS)
MonthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan-Meier Estimate of Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Hazard ratio (hr): 0.59 · 95% CI 0.37 to 0.95
SecondaryPercentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC

Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.

Time frame:
From date of first dose to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC
Percentage of ParticipantsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC77.5 (70.7 to 83.4)53.3 (45.8 to 60.8)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Cochran-Mantel-Haenszel · p = < 0.0001Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \> 2 years), and disease histology (FL, MZL).
SecondaryPercentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC

Percentage of participants with a best response of at CR during the study without administration of new anti-lymphoma therapy. A CR = Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.

Time frame:
From date of first dose up to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC
Percentage of ParticipantsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC33.7 (26.8 to 41.2)18.3 (13.0 to 24.8)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Cochran-Mantel-Haenszel · p = = 0.0010Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \> 2 years), and disease histology (FL, MZL).
SecondaryKaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC

Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.

Time frame:
From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Reported as:
Median · months
Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC
monthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC36.6 (22.9 to NA)21.7 (12.8 to 27.6)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Log Rank · p = 0.0015 · Hazard ratio (hr): 0.53 · 95% CI 0.36 to 0.79
SecondaryKaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC

DOCR was defined as the time from initial CR until documented PD or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.

Time frame:
From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Reported as:
Median · months
Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC
monthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRCNA (25.3 to NA)NA (13.8 to NA)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Log Rank · p = 0.2993 · Hazard ratio (hr): 0.68 · 95% CI 0.32 to 1.43
SecondaryKaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC

Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date.

Time frame:
From date of randomization to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Reported as:
Median · months
Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC
monthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC27.6 (22.1 to NA)13.9 (11.4 to 16.7)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Stratified Log-Rank Test · p = < 0.0001 · Hazard ratio (hr): 0.51 · 95% CI 0.38 to 0.67Hazard ratio and its CI were estimated from Cox proportional hazard model adjusting for the stratification factors noted above.
SecondaryKaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)

Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study.

Time frame:
From date of randomization to date of first documented administration of a new anti-lymphoma treatment (Average of 55.71 months and a maximum up to 95.2 months)
Reported as:
Median · Months
Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)
MonthsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)73.1 (43.0 to NA)31.8 (22.2 to 39.4)
Statistical analysis
  • Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo · Stratified Log Rank Test · p = <0.0001 · Hazard ratio (hr): 0.53 · 95% CI 0.39 to 0.71Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \> 2 years), and disease histology (FL, MZL).
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs include AEs that started or worsened between the date of the first dose and 28 days after the date of the last dose. A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death

Time frame:
From first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsRituximab + Lenalidomide (R^2)Rituximab + Placebo
Any TEAE174173
Any TEAE Related to Lenalidomide/Placebo (LEN/PBO)159118
Any TEAE Related to Rituximab (RIT)134105
Any Serious TEAE4525
Any Serious TEAE Related to LEN/PBO238
Any Serious TEAE Related to RIT134
Any CTCAE Grade (GR) 3/4 TEAE12158
Any CTCAE GR 3/4 TEAE Related to LEN/PBO10138
Any CTCAE GR 3/4 TEAE Related to RIT5720
Any GR 5 TEAE22
Any TEAE Leading to Dose Reduction LEN/PBO466
Any TEAE Leading to Dose Interruption LEN/PBO11347
Any TEAE Leading to Dose Interruption RIT5938
Any TEAE Leading to Discontinuation of LEN/PBO159
Any TEAE Leading to Discontinuation of RIT62

Adverse events

Collected over Other (Not including Serious) Adverse Events (AEs) and Serious Adverse Events (SAEs) are collected from first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 100 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Lenalidomide (R^2)27/178 (15.2%)45/176 (25.6%)170/176 (96.6%)
Rituximab + Placebo47/180 (26.1%)25/180 (13.9%)158/180 (87.8%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventRituximab + Lenalidomide (R^2)Rituximab + Placebo
PneumoniaInfections and infestations6/1766/180
Febrile neutropeniaBlood and lymphatic system disorders5/1760/180
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/1761/180
NeutropeniaBlood and lymphatic system disorders3/1760/180
PyrexiaGeneral disorders3/1760/180
SepsisInfections and infestations3/1762/180
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1763/180
AnaemiaBlood and lymphatic system disorders2/1760/180
Supraventricular tachycardiaCardiac disorders2/1760/180
General physical health deteriorationGeneral disorders2/1761/180
Most frequent other events
Showing 10 of 55
Most frequent other events
EventRituximab + Lenalidomide (R^2)Rituximab + Placebo
NeutropeniaBlood and lymphatic system disorders103/17640/180
DiarrhoeaGastrointestinal disorders55/17642/180
ConstipationGastrointestinal disorders46/17625/180
CoughRespiratory, thoracic and mediastinal disorders40/17631/180
FatigueGeneral disorders38/17633/180
LeukopeniaBlood and lymphatic system disorders37/17618/180
PyrexiaGeneral disorders35/17627/180
Upper respiratory tract infectionInfections and infestations33/17623/180
PruritusSkin and subcutaneous tissue disorders33/1768/180
AnaemiaBlood and lymphatic system disorders28/1768/180

Baseline characteristics

The intent to treat (ITT) population was defined as all participants who were randomized into the trial, regardless of whether they received investigational product (IP) or not.

Age, Continuous
Age, Continuous(Years)Rituximab + Lenalidomide (R^2)Rituximab + PlaceboTotal
Mean62.30 ± 11.22761.48 ± 11.16061.89 ± 11.186
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Lenalidomide (R^2)Rituximab + PlaceboTotal
Female10383186
Male7597172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rituximab + Lenalidomide (R^2)Rituximab + PlaceboTotal
Hispanic or Latino242044
Not Hispanic or Latino147158305
Unknown or Not Reported729
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rituximab + Lenalidomide (R^2)Rituximab + PlaceboTotal
White118115233
Other Races5464118
Not Collected or Reported617
08

Study locations

160 sites
  • Mitchell Cancer Center, University of South Alabama
    Mobile, Alabama 36604, United States
  • Arizona Center for Cancer Care
    Glendale, Arizona 85306, United States
  • Southwest Cancer Care Medical Group
    Escondido, California 92025, United States
  • Marin Oncology Associates
    Greenbrae, California 94904-2007, United States
  • Wilshire Oncology Medical Group, Inc
    La Verne, California 91750, United States
  • North County Hematology Oncology (NCHO) - TRM, LLC.
    Oceanside, California 92056, United States
  • Hematology-Oncology Medical Group of Orange County, Inc.
    Orange, California 92868, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Wellness Hematology Oncology
    West Hills, California 92056, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Florida Cancer Specialists North Region Sarah Cannon Research
    Saint Petersburg, Florida 33705, United States
  • Illinois Cancer Care, P.C.
    Peoria, Illinois 61615, United States
  • LRG Healthcare Oncology Clinic
    Laconia, Indiana 03246, United States
  • Iowa Oncology Research Association
    Des Moines, Iowa 50309, United States
  • University of Louisville, J.G. Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Providence Cancer Institute
    Southfield, Michigan 48075, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Coborn Cancer Center at the St. Cloud Hospital
    Saint Cloud, Minnesota 56303, United States
  • NH Oncology - Hematology, PA
    Hooksett, New Hampshire 03106, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hematology-Oncology Associates of Northern NJ
    Morristown, New Jersey 07962, United States
  • University of New Mexico
    Albuquerque, New Mexico 87102, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Oncology Hematology Care Sarah Cannon Research
    Cincinnati, Ohio 45242, United States
  • Local Institution - 028
    Portland, Oregon 97213, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • St Francis Hospital
    Greenville, South Carolina 29607, United States
  • Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute
    Spartanburg, South Carolina 29303, United States
  • Sarah Cannon Research Inst
    Nashville, Tennessee 37203, United States
  • Arlington Cancer Center
    Arlington, Texas 76012, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Northwest Medical Specialties PLLC
    Tacoma, Washington 98405, United States
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Local Institution - 371
    Gent, 9000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • CHU Mont -Godinne
    Yvoir, 5530, Belgium
  • Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento
    Porto Alegre, Rio Grande Do Sul 90035-001, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Associacao Educudora Sao Carlos AESC Hospital Giovanni Battista HGB Hospital Mae de Deus Center
    Porto Alegre, Rio Grande Do Sul 90740-340, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú
    Jau/SP, São Paulo 17210-080, Brazil
  • MS INCA HC I Hospital do Cancer I
    Rio De Janeiro, 20231-130, Brazil
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    São Paulo, 01308 050, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia
    São Paulo, 01321-001, Brazil
  • Fundação Antonio Prudente - AC Camargo Câncer center
    São Paulo, 01509-900, Brazil
  • Beijing Cancer Hospital
    Beijing, PR, 100142, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • 307 Hospital of PLA
    Beijing, 100071, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • The Third Xiangya hospital of central south university
    Changsha, 410013, China
  • West China Hospital of Sichuan University
    Chengdu, 610041, China
  • Fujian Medical University Union Hospital
    Fuzhou, 350001, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, 510060, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Local Institution - 600
    Guangzhou, 510080, China
  • The First Affiliated Hospital of Medical School of Zhejiang University
    Hangzhou City, 310003, China
  • Local Institution - 604
    Hangzhou City, 310006, China
  • Jiangsu Province Hospital The First Hospital affiliated with Nanjing Medical University
    Nanjing, 210029, China
  • Cancer Hospital, Fudan University
    Shanghai, 200032, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, 215006, China
  • Chinese Academy of Medical Sciences & Peking Union Medical College
    Tianjin, 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, 300060, China
  • Xijing Hospital
    Xi'an, 710032, China
  • Interni hematoonkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove, IV.interni hematologicka klinika
    Hradec Kralove, 500 05, Czechia
  • Fakultni Nemocnice Ostrava, Klinika hematoonkologie,
    Ostrava, 70852, Czechia
  • Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika
    Prague 10, 100 34, Czechia
  • Local Institution - 534
    Praha, 128 08, Czechia
  • Vseobecna Fakultni Nemocnice v Praze
    Praha, 128 08, Czechia
  • CHU d'Angers
    Angers, 49033, France
  • Centre Hospitalier Universitaire d'Avicennes
    Bobigny Cedex, 93009, France
  • CHRU de Brest - Hopital Morvan
    Brest Cedex, 29609, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • CH Perpignan - Hopital Saint-Jean
    Perpignan, 66046, France
  • CHU de Poitiers
    Poitiers, 86021, France
  • Centre Hospitalier de Valence
    Valence, 26953, France
  • Charite - Universitaetsmedizin Berlin Charité - Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Charite - Universitaetsmedizin Berlin Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Krankenhaus Nordwest
    Frankfurt, 60488, Germany
  • Onkologische Schwerpunktpraxis Leer - Emden
    Leer, 26789, Germany
  • Kliniken Maria Hilf GmbH
    Mönchengladbach, 41063, Germany
  • Klinkum der Stadt Villingen-Schwenningen GmbH
    Villingen-Schwenningen, 78052, Germany
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Hadassah University Hospital
    Jerusalem, 91120, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel-Aviv, 64239, Israel
  • Centro di Riferimento Oncologico - IRCCS
    Aviano (PN), 33081, Italy
  • U.O.C. Ematologia
    Barletta, 76121, Italy
  • A.O.U. di Bologna Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi - Nesima
    Catania, 95124, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)
    Meldola, 47014, Italy
  • Istituto Europeo di Oncologia - IEO
    Milano, 20141, Italy
  • Ospedale Niguarda Ca Granda
    Milano, 20162, Italy
  • IRCCS- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione "G. Pascale"
    Napoli, 80131, Italy
  • Az. Osp. Vincenzo Cervello
    Palermo, 90146, Italy

Showing the first 100 of 160 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, Lopez-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, Andre M, Zachee P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PubMed 30184451 ↗
  • Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabecadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. PubMed 30897038 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jun 2018, 55 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 55 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2013
First posted
Sep 10, 2013
StartActual
Nov 21, 2013
Primary completionActual
Jun 22, 2018
CompletionActual
Jan 26, 2022
Results first posted
Aug 13, 2019
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01938001
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 10, 2013
Start date
Nov 21, 2013
Primary completion
Jun 22, 2018
Completion
Jan 26, 2022
Results posted
Aug 13, 2019
Last update
Feb 22, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion